학술논문
Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.
Document Type
Article
Author
Kasumba, Irene N; Badji, Henry; Powell, Helen; Hossain, M Jahangir; Omore, Richard; Sow, Samba O; Verani, Jennifer R; Platts-Mills, James A; Widdowson, Marc-Alain; Zaman, Syed M A; Jones, Jennifer; Sen, Sunil; Permala-Booth, Jasnehta; Nasrin, Shamima; Roose, Anna; Nasrin, Dilruba; Ochieng, John Benjamin; Juma, Jane; Doh, Sanogo; Jones, Joquina Chiquita M
Source
Subject
*ANTIBIOTICS
*REVERSE transcriptase polymerase chain reaction
*CEFTRIAXONE
*STATISTICAL significance
*DIARRHEA
*CO-trimoxazole
*CIPROFLOXACIN
*DRUG resistance
*FISHER exact test
*MANN Whitney U Test
*SEROTYPES
*AMPICILLIN
*CHI-squared test
*DESCRIPTIVE statistics
*RESEARCH funding
*SHIGELLOSIS
*QUINOLONE antibacterial agents
*AZITHROMYCIN
*DATA analysis software
*SHIGELLA
*MICROBIAL sensitivity tests
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Background: We evaluated the burden of Shigella spp from children aged 0–59 months with medically attended moderate-to-severe diarrhea and matched controls at sites in Mali, The Gambia, and Kenya participating in the Vaccine Impact on Diarrhea in Africa (VIDA) study from 2015 to 2018. Methods: Shigella spp were identified using coprocultures and serotyping in addition to quantitative polymerase chain reaction (qPCR). Episode-specific attributable fractions (AFe) for Shigella were calculated using Shigella DNA quantity; cases with AFe ≥0.5 were considered to have shigellosis. Results: The prevalence of Shigella was determined to be 359 of 4840 (7.4%) cases and 83 of 6213 (1.3%) controls by culture, and 1641 of 4836 (33.9%) cases and 1084 of 4846 (22.4%) controls by qPCR (cycle threshold <35); shigellosis was higher in The Gambia (30.8%) than in Mali (9.3%) and Kenya (18.7%). Bloody diarrhea attributed to Shigella was more common in 24- to 59-month-old children (50.1%) than 0- to 11-month-old infants (39.5%). The Shigella flexneri serogroup predominated among cases (67.6% of isolates), followed by Shigella sonnei (18.2%), Shigella boydii (11.8%), and Shigella dysenteriae (2.3%). The most frequent S. flexneri serotypes were 2a (40.6%), 1b (18.8%), 6 (17.5%), 3a (9.0%), and 4a (5.1%). Drug-specific resistance among 353 (98.3%) Shigella cases with AMR data was as follows: trimethoprim-sulfamethoxazole (94.9%), ampicillin (48.4%), nalidixic acid (1.7%), ceftriaxone (0.3%), azithromycin (0.3%), and ciprofloxacin (0.0%). Conclusions: A high prevalence of shigellosis continues in sub-Saharan Africa. Strains are highly resistant to commonly used antibiotics while remaining susceptible to ciprofloxacin, ceftriaxone, and azithromycin. We evaluated the burden of Shigella spp from children 0–59 months with medically attended moderate-to-severe diarrhea and matched controls at sites in Mali, The Gambia, and Kenya participating in the Vaccine Impact on Diarrhea in Africa study from 2015 to 2018. [ABSTRACT FROM AUTHOR]